FDA Drug Approval Process
Complete Guide for Biotech Investors
From IND application to post-market surveillance, the FDA drug approval process takes 10-15 years and costs an average of $2.6 billion. For biotech investors, understanding each stage's success rates, timelines, and stock price impact is essential. This guide covers the entire pipeline with real data.
- The FDA Approval Pipeline at a Glance
- Preclinical Research: Before Human Trials
- Phase 1: Safety and Dosing
- Phase 2: Efficacy and Side Effects
- Phase 3: The Pivotal Trial
- NDA/BLA Submission and FDA Review
- The PDUFA Date: Decision Day
- Post-Approval: Phase 4 and REMS
- Success Rates by Phase and Therapeutic Area
- How Each Stage Affects Stock Prices
- Accelerated Pathways: Breakthrough, Fast Track, and More
- FAQ
The FDA Approval Pipeline at a Glance
Every drug sold in the United States must be approved by the Food and Drug Administration (FDA). The approval process is one of the most rigorous regulatory pipelines in the world, designed to ensure that drugs are both safe and effective before reaching patients. For investors, this pipeline creates a series of binary catalysts — each stage is a go/no-go decision that can move a biotech stock dramatically.
The cumulative probability of a drug making it from Phase 1 to FDA approval is approximately 7.9% across all therapeutic areas, according to data from BIO, Informa Pharma Intelligence, and QLS analysis. This means for every 100 drugs entering human trials, fewer than 8 will ever reach patients.
Preclinical Research: Before Human Trials
Before a drug can be tested in humans, it must pass through extensive preclinical research. This includes laboratory studies (in vitro) and animal studies (in vivo) to evaluate the drug's safety profile, mechanism of action, and potential efficacy. Preclinical work typically takes 3-6 years and involves:
- Target identification and validation — identifying the biological target (protein, gene, receptor) that the drug will act on
- Lead compound optimization — refining the chemical or biological compound for optimal potency, selectivity, and drug-like properties
- Pharmacology and toxicology studies — testing the drug in animal models to assess safety, dosing, metabolism, and potential toxicity
- Manufacturing process development — developing a scalable process to produce the drug under Good Manufacturing Practice (GMP) conditions
At the end of preclinical work, the company files an Investigational New Drug (IND) application with the FDA. The IND contains all preclinical data, the proposed clinical trial protocol, and manufacturing information. The FDA has 30 days to review the IND and place a clinical hold or allow the trial to proceed. If the FDA does not respond within 30 days, the company may begin dosing patients.
For investors, an IND filing or IND acceptance is a minor positive catalyst. It signals that the company has completed preclinical work and is ready to test in humans, but the drug is still very early-stage with a long road to approval.
Phase 1: Safety and Dosing
Phase 1 trials are the first time a drug is tested in humans. The primary goal is safety, not efficacy. Phase 1 trials typically enroll 20-100 healthy volunteers (or patients with the target disease for oncology drugs) and test escalating doses to determine:
- Maximum tolerated dose (MTD)
- Dose-limiting toxicities (DLTs)
- Pharmacokinetics (how the body absorbs, distributes, metabolizes, and excretes the drug)
- Pharmacodynamics (how the drug affects the body at different doses)
Phase 1 trials typically take 1-2 years and cost $15-30M. The success rate from Phase 1 to Phase 2 is approximately 52%. Failures at this stage are usually due to safety concerns — unacceptable toxicity at doses needed for efficacy.
Stock price impact: Phase 1 data rarely moves stocks dramatically unless the drug shows exceptional early efficacy signals (particularly in oncology, where Phase 1 trials in cancer patients may show tumor shrinkage). A Phase 1 safety halt, however, can crash a stock 40-60% as it signals fundamental drug toxicity problems.
Phase 2: Efficacy and Side Effects
Phase 2 is the first real test of whether a drug works. These trials enroll 100-300 patients with the target disease and measure the drug's efficacy against specific endpoints while continuing to monitor safety. Phase 2 trials often:
- Test multiple doses to find the optimal dose for Phase 3
- Use a control group (placebo or standard of care) for comparison
- Measure preliminary efficacy endpoints (biomarkers, tumor response, symptom improvement)
- Identify the patient population most likely to benefit
Phase 2 trials take 2-3 years and cost $20-50M. The success rate from Phase 2 to Phase 3 is approximately 28.9% — making this the stage with the highest attrition rate. The majority of drugs that fail do so in Phase 2 because they simply do not show sufficient efficacy to justify the massive investment of a Phase 3 trial.
Phase 2 is the "Valley of Death" in drug development. Only about 29% of drugs advance from Phase 2 to Phase 3. Positive Phase 2 data is one of the most significant catalysts in biotech investing because it dramatically improves the probability of the drug eventually reaching market.
Phase 3: The Pivotal Trial
Phase 3 trials are the final and largest stage of clinical testing before a drug can be submitted for FDA approval. These are pivotal trials — their results form the primary basis for the FDA's approval decision. Phase 3 trials typically:
- Enroll 300-3,000+ patients (sometimes 10,000+ for cardiovascular or diabetes drugs)
- Are randomized, double-blinded, and placebo-controlled
- Run across dozens to hundreds of clinical sites in multiple countries
- Measure definitive clinical endpoints (overall survival, progression-free survival, disease remission)
- Take 3-4 years and cost $50-300M+
The success rate from Phase 3 to NDA/BLA submission is approximately 57.8%. Failures at this stage are the most devastating for biotech stocks because of the massive time and capital investment. A Phase 3 failure can erase 60-90% of a company's market cap in a single day, especially for single-asset biotechs.
Companies like MRNA demonstrated the transformative value of successful Phase 3 trials, while Phase 3 failures have destroyed billions in shareholder value across the sector. The Phase 2 vs Phase 3 comparison guide covers the critical differences between these stages in detail.
NDA/BLA Submission and FDA Review
After successful Phase 3 trials, the company compiles all clinical, preclinical, and manufacturing data into either an NDA (New Drug Application) for small-molecule drugs or a BLA (Biologics License Application) for biological products. These applications can be hundreds of thousands of pages long.
The FDA review process works as follows:
- Day 0 — Submission: Company files the NDA/BLA with the FDA and pays the PDUFA user fee (approximately $4.0M in FY2026)
- Day 60 — Filing Decision: FDA decides whether to accept the application for review ("file") or issue a Refuse to File (RTF) letter requesting additional data
- PDUFA Date Set: If accepted, the review clock begins. Standard review: 10 months from Day 60. Priority review: 6 months from Day 60
- Mid-Cycle Review: FDA may request additional analyses, hold pre-approval manufacturing inspections, and schedule advisory committee meetings
- PDUFA Date — Decision: FDA issues approval, a Complete Response Letter (CRL), or extends the review
The approval rate for drugs that reach NDA/BLA submission is approximately 90.4%, making this the highest-probability stage. However, the 10% that fail at this stage (receiving a CRL) experience some of the most dramatic stock declines in all of investing.
The PDUFA Date: Decision Day
The PDUFA date is the FDA's deadline to make a decision on the drug application. It is the single most important catalyst in biotech investing. On this date, the FDA will either:
- Approve the drug for commercial sale (stock typically gaps up 20-200%+)
- Issue a Complete Response Letter (CRL) requesting more data (stock typically drops 40-80%)
- Extend the review by 3 months for additional analysis (stock typically drops 10-30%)
Track all upcoming PDUFA dates across the biotech sector on the BiotechSigns FDA Catalyst Calendar. For a deep dive into PDUFA mechanics, see the complete PDUFA guide.
Post-Approval: Phase 4 and REMS
After FDA approval, the drug enters the market but oversight continues:
- Phase 4 (post-marketing studies): The FDA may require additional studies to monitor long-term safety, effectiveness in broader populations, or optimal dosing. These are sometimes called post-marketing commitments (PMCs) or post-marketing requirements (PMRs).
- REMS (Risk Evaluation and Mitigation Strategies): For drugs with serious safety concerns, the FDA may require a REMS program that includes patient registries, prescriber training, restricted distribution, or medication guides.
- Label expansions: Companies often run additional trials to expand the approved indications (new disease areas, new patient populations). Each label expansion requires a supplemental NDA (sNDA) with its own PDUFA date.
- Safety monitoring: The FDA can issue safety warnings, require label changes, restrict use, or in rare cases withdraw approval if post-market data reveals serious safety issues.
Success Rates by Phase and Therapeutic Area
Success rates vary significantly by therapeutic area. Based on data from BIO/Informa/QLS analysis of clinical trials from 2011-2020:
| Therapeutic Area | Phase 1→Approval | Phase 2 Success | Phase 3 Success |
|---|---|---|---|
| Hematology | 23.9% | 43.2% | 67.4% |
| Infectious Disease | 19.1% | 36.8% | 64.2% |
| Ophthalmology | 13.3% | 30.6% | 57.1% |
| Rare/Orphan Disease | 17.1% | 38.7% | 62.5% |
| Neurology | 5.9% | 20.1% | 49.3% |
| Oncology | 5.3% | 18.7% | 44.8% |
| Psychiatry | 6.2% | 19.5% | 51.4% |
| Overall Average | 7.9% | 28.9% | 57.8% |
Notice that oncology has the lowest overall success rate (5.3%) but dominates the biotech pipeline because of the enormous commercial opportunity and accelerated regulatory pathways for cancer drugs. Hematology has the highest success rate, partly because blood cancers have well-defined biomarkers and endpoints.
How Each Stage Affects Stock Prices
Understanding the typical stock price impact at each stage helps investors calibrate their risk-reward expectations:
Clinical trial results are inherently unpredictable. Past stock price movements at specific stages are not predictive of future performance. A Phase 3 trial with a 58% historical success rate still fails 42% of the time. Position sizing and diversification are critical when investing around binary clinical catalysts. Nothing in this guide is investment advice.
Accelerated Pathways: Breakthrough, Fast Track, and More
The FDA offers several accelerated development and review programs for drugs addressing serious or life-threatening conditions:
When a company announces that it has received Breakthrough Therapy designation from the FDA, it signals that the drug has shown substantial clinical improvement over existing treatments. This is one of the most reliable positive catalysts in biotech, often causing 15-40% stock price gains. Use the BiotechSigns Signals feed to track these designations in real time.
BiotechSigns monitors PDUFA dates, clinical trial readouts, AdCom votes, and FDA designations across 8,000+ biotech companies. Never miss a catalyst.